EMEA-003320-PIP01-22 - paediatric investigation plan

ezeprogind

Key facts

• Active substance:
  ezeprogind
• Therapeutic area:
  Neurology
• Decision number:
  P/0538/2022
• PIP number:
  EMEA-003320-PIP01-22
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of progressive supranuclear palsy
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  30/12/2022
• Compliance check done:
  No

Decision

P/0538/2022 : EMA decision of 30 December 2022 on the granting of a product specific waiver for ezeprogind (EMEA-003320-PIP01-22)

Adopted Reference Number: EMA/931324/2022